Nova MSC Bhd’s subsidiary, EyRIS, has won a RM7.13 million contract from JPMCnova Sdn Bhd to implement Brunei’s National Diabetic Retinopathy (DR) Screening Program.

Starting October 2024, the five-year project will use EyRIS’ AI platform, EySCAN and SELENA+, to enhance early detection of DR across Brunei’s healthcare facilities.

This initiative is aimed at addressing the growing diabetic population in Brunei and improving vision care. –TMR